BioSpace News Archive

Aura Biosciences Inc. announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in a fireside chat at the JMP Securities Life Sciences Conference on Tuesday, May 16, 2023, at 2:00 p.m. ET.

Impel Pharmaceuticals Inc. (NASDAQ: IMPL) today reported financial results for the first quarter ended March 31, 2023 and provided a business update.

Salarius Pharmaceuticals, Inc. announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 3,636,364 shares of its common stock, Series A-1 warrants to purchase up to an aggregate of 3,636,364 shares of common stock and Series A-2 warrants to purchase up to an aggregate of 3,636,364 shares of common stock at a purchase price of $1.65 per share and accompanying warrants in a private placement priced at-the-market under Nasdaq rules.

Sunshine Biopharma Inc. announced that it entered into a securities purchase agreement with a single healthcare-focused institutional investor for aggregate gross proceeds of approximately $5 million, before deducting fees to the placement agent and other offering expenses payable by the Company.

IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced financial results and operational highlights for the first quarter ended March 31, 2023.

SCYNEXIS, Inc. (NASDAQ: SCYX) today announced the closing of its previously announced exclusive license agreement with GSK plc (LSE/NYSE: GSK) to commercialize the novel antifungal BREXAFEMME® (ibrexafungerp tablets) as a treatment for vulvovaginal candidiasis (VVC) and further develop ibrexafungerp for multiple indications in invasive and life-threatening fungal diseases.

Vaccitech plc (NASDAQ: VACC) (the Company, we or us) today announced its financial results for the first quarter of 2023 and an overview of the Company’s progress.

SOFIE Biosciences (SOFIE), an established US manufacturer and developer of radiopharmaceuticals, has dosed and imaged the first patient with [18F]FAPI-74 in its US Clinical Trial of flourine-18 labeled Fibroblast Activation Protein Inhibitor (FAPI).

Delcath Systems, Inc. (Nasdaq: DCTH) (Delcath or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and certain preliminary financial results for the first quarter ended March 31, 2023.

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today announced the appointment of Mark A. Glickman to its Board of Directors, effective as of May 11, 2023.